The COVID Pandemic has been largely achieved by the falsification of the existence of a virus and the existence of a test (RT-PCR) that can detect the non-existent virus. The solution to this fabricated pandemic is a vaccine for a non-existent virus
by Jon Rappoport
April 24, 2020
(To join our email list, click here.)
Canadian author and independent researcher, David Crowe, has spent several decades analyzing and torpedoing SPECIFICS of conventional medical research. At the deepest level.
I’m talking about, for example, the mainstream claims of discovering new viruses.
Crowe doesn’t lay on vague brushstrokes. He goes to the core of fabrications and exposes them, chapter and verse.
His new paper, which he continues to update and expand, is: “Flaws in Coronavirus Pandemic Theory”.
Here I quote from the section of his paper where he takes up the question of discovery—have researchers actually found a new virus which they assert is the cause of a new pandemic, COVID-19?
At the end of this article, I list the published papers Crowe refers to by number, as he takes apart the very basis of the COVID illusion.
David Crowe: “Scientists are detecting novel RNA in multiple patients with pneumonia-like conditions, and are assuming that the detection of RNA (which is believed to be wrapped in proteins to form an RNA virus, as coronaviruses are believed to be) is equivalent to isolation of the virus. It is not, and one of the groups of scientists was honest enough to admit this”:
“’we did not perform tests for detecting infectious virus in blood’” 
“But, despite this admission, earlier in the paper they repeatedly referred to the 41 cases (out of 59 similar cases) that tested positive for this RNA as, ‘41 patients…confirmed to be infected with 2019-nCoV’.”
“Another paper quietly admitted that”:
“’our study does not fulfill Koch’s postulates’” 
Here’s the Company That’s the Closest to developing a Zika Vaccine
by Laura Lorenzetti January 28, 2016, 5:37 PM E
[Full article copied for archival purposes, is informational and non-commercial]
The Zika virus has spread rapidly across the Americas, arriving in Brazil last May and creeping into 22 other countries and territories around the region. The virus’ spread has been accompanied by a steep increase in babies born with abnormally small heads and in cases of Guillain-Barre syndrome, an uncommon nervous system disease. This has raised the alarm among public health officials around the world—and launched the quest for a vaccine that could stop its spread.
The U.S. and international governments are pushing forward with programs for Zika vaccines, and at least three pharmaceutical companies are either considering or actively pursing programs, including giants GlaxoSmithKlineGSK, and Sanofi SNY. But the company that appears to be the farthest along is a relatively small $500 million market cap biotech named Inovio Pharmacuetucals INO. Wall Street has shown interest in the company. Inovio’s stock was up about 8% today on news that it is entering clinical trials with its MERS vaccine, which could also hold promise for a future Zika vaccine.
Nonetheless, even Inovio is likely a ways off from developing a human Zika vaccine.
“It is important to understand that we will not have a widely available, safe, and effective Zika vaccine this year, and probably not even in the next few years,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said in a press conference.
The advantage of Zika vaccine programs is that they can use similar mosquito-based diseases, part of a family called flaviviruses, like dengue, West Nile virus, and chikungunya as a “jumping off” point. While researchers are currently trying to learn more about the basics of the Zika virus and its effects on the human body given how new the disease is, they can already use past vaccine development platforms from other flaviviruses as a foundation since they spread in similar ways.
NIAID is already working on two approaches: a DNA-based vaccine, similar to a strategy used for West Nile virus, which has been found safe and effective in a phase one trial. It is also working on a more traditional killed virus-vaccine, similar to those already developed to prevent dengue.
Traditional killed-virus(?) vaccines, also called live-attenuated vaccines, are what most of us are used to. They are grown in eggs using live viruses, and then made inactive by a chemical process, and are the basis for the vast majority of vaccines we take as children and annually to prevent the flu. They are time intensive to develop, typically requiring between 10 and 15 years before they are approved, according to GlaxoSmithKline.
DNA-based vaccines, on the other hand, can reduce that development time by creating a synthetic DNA sequence in a lab that can trigger the human body to create the same antigens as from a killed virus. This cuts development time since it doesn’t need to grow a live virus, which can have unpredictable development pathways.
Inovio Pharmaceuticals has also been working on a DNA-based vaccine for Zika since December. In that time, Inovio has created a DNA strand that can potentially prevent the virus, using its knowledge from its dengue virus program. It is now testing the vaccine in mice and plans to move into testing primates “in the next few weeks,” said Inovio CEO J. Joseph Kim. Once its safety is confirmed, the vaccine will move into phase one testing in humans—as soon as the end of 2016.
“The beauty of this technological platform is that the vaccine is simply a DNA sequence developed in water,” said Kim. “It cuts through all the difficult handling and complex development times of traditional vaccine approaches.”
Inovio has taken this same approach with an Ebola vaccine, going from “bench to clinic”—researcher terms, meaning from initial creation to human testing—in just over 18 months. That program attracted the interest of the U.S. Defense Advanced Research Projects Agency (DARPA), which gave the company $45 million to support the program’s ongoing development. The biotech is also working on a DNA-based vaccine for MERS, which has gone from its creation in a lab to a phase one trial at Walter Reed Army Institute of Research in just over a year.
Still, while animal applications of these preventatives have been approved in animals, DNA-based vaccines are one of the latest medical advancements, and one has yet to be approved for use in humans in the U.S. Even though Inovio has attracted fans on Wall Street, it still has a lot to prove.
Note: Open declaration that the synthetic virologists can and will create viruses or virus fragments to pollute, contaminate your sovereign earthly vehicle for profit!
Don’t forget in the US they are indemnified against lawsuits. They are protected from any harm or damage that their synthetic DNA vaccines cause. A BIG MORAL HAZARD.